INAB · Insider Trading
IN8bio, Inc. Common Stock
Every open-market purchase and sale reported by INAB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-29 | Emily Fairbairn | Director | G | −724,637 | — |
| 2026-05-12 | Luba Greenwood | Director | A | +22,000 deriv. | — |
| 2026-05-12 | William Tai-Wei Ho | CEO | A | +154,500 deriv. | — |
| 2026-05-12 | Patrick McCall | CHIEF FINANCIAL OFFICER | A | +56,250 deriv. | — |
| 2026-05-12 | Jeremy R. Graff | Director | A | +22,000 deriv. | — |
| 2026-05-12 | Lawrence Lamb | EVP and CSO | A | +54,000 deriv. | — |
| 2026-05-12 | Kate Rochlin | President and COO | A | +60,000 deriv. | — |
| 2026-05-12 | Corinne Epperly | Director | A | +22,000 deriv. | — |
| 2026-05-12 | Emily Fairbairn | Director | A | +22,000 deriv. | — |
| 2026-05-12 | Peter C. Brandt | Director | A | +22,000 deriv. | — |
| 2026-02-06 | Kate Rochlin | President and COO | A | +80,000 deriv. | — |
| 2026-02-06 | Lawrence Lamb | EVP and CSO | A | +72,000 deriv. | — |
| 2026-02-06 | Patrick McCall | CHIEF FINANCIAL OFFICER | A | +75,000 deriv. | — |
| 2026-02-06 | William Tai-Wei Ho | CEO | A | +206,000 deriv. | — |
| 2025-12-23 | Patrick McCall | CHIEF FINANCIAL OFFICER | A | +7,247 | +$10.00K |
| 2025-12-23 | Alan S. Roemer | Director | A | +36,232 | +$50.00K |
| 2025-12-23 | Peter C. Brandt | Director | A | +72,464 | +$100.00K |
| 2025-12-23 | Kate Rochlin | Chief Operating Officer | A | +7,247 | +$10.00K |
| 2025-12-23 | Emily Fairbairn | Director | A | +724,637 | +$1000.00K |
| 2025-12-23 | William Tai-Wei Ho | PRESIDENT AND CEO | A | +36,232 | +$50.00K |
| 2025-05-12 | Peter C. Brandt | Director | A | +63,150 deriv. | — |
| 2025-05-12 | Alan S. Roemer | Director | A | +63,150 deriv. | — |
| 2025-05-12 | Emily Fairbairn | Director | A | +63,150 deriv. | — |
| 2025-05-12 | Jeremy R. Graff | Director | A | +63,150 deriv. | — |
| 2025-05-12 | Corinne Epperly | Director | A | +63,150 deriv. | — |
| 2025-05-12 | Luba Greenwood | Director | A | +63,150 deriv. | — |
| 2025-05-07 | Peter C. Brandt | Director | M | +163,934 | +$30.23K |
| 2025-05-07 | Lawrence Lamb | EVP and CSO | MIXED | — | — |
| 2025-05-07 | Kate Rochlin | Chief Operating Officer | M | +12,295 | +$2.27K |
| 2025-05-07 | Patrick McCall | CHIEF FINANCIAL OFFICER | M | +15,000 | +$2.77K |
| 2025-05-07 | William Tai-Wei Ho | PRESIDENT AND CEO | MIXED | — | — |
| 2025-05-07 | Corinne Epperly | Director | MIXED | — | — |
| 2025-05-07 | Jeremy R. Graff | Director | MIXED | — | — |
| 2025-05-07 | Alan S. Roemer | Director | M | +113,459 | +$20.92K |
| 2025-05-07 | BIOS Equity Partners III, LP | 10%+ Owner | MIXED | — | — |
| 2025-05-07 | BIOS Incysus Co-Invest I, LP | 10%+ Owner | MIXED | — | — |
| 2025-02-07 | William Tai-Wei Ho | PRESIDENT AND CEO | A | +912,450 deriv. | — |
| 2025-02-07 | Kate Rochlin | Chief Operating Officer | A | +338,950 deriv. | — |
| 2025-02-07 | Patrick McCall | CHIEF FINANCIAL OFFICER | A | +343,000 deriv. | — |
| 2025-02-07 | Lawrence Lamb | EVP and CSO | A | +306,750 deriv. | — |
| 2024-12-23 | Peter C. Brandt | Director | A | +49,490 deriv. | — |
| 2024-12-23 | Corinne Epperly | Director | A | +37,655 deriv. | — |
| 2024-12-23 | Luba Greenwood | Director | A | +39,449 deriv. | — |
| 2024-12-23 | Jeremy R. Graff | Director | A | +47,697 deriv. | — |
| 2024-12-23 | William Tai-Wei Ho | PRESIDENT AND CEO | A | +1,188,282 deriv. | — |
| 2024-12-23 | Travis Whitfill | Director | A | +42,676 deriv. | — |
| 2024-12-23 | Alan S. Roemer | Director | A | +93,242 deriv. | — |
| 2024-12-23 | Patrick McCall | CHIEF FINANCIAL OFFICER | A | +290,085 deriv. | — |
| 2024-12-23 | Lawrence Lamb | EVP and CSO | A | +286,899 deriv. | — |
| 2024-12-23 | Kate Rochlin | Chief Operating Officer | A | +302,839 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| BIOS Incysus Co-Invest I, LP | 10%+ Owner | 124,253 | $119.97K |
| William Tai-Wei Ho | CEO | 123,601 | $119.34K |
| Peter C. Brandt | Director | 98,690 | $95.29K |
| Alan S. Roemer | Director | 49,514 | $47.81K |
| BIOS Equity Partners III, LP | Director | 19,148 | $18.49K |
| Patrick McCall | CHIEF FINANCIAL OFFICER | 9,482 | $9.15K |
| Kate Rochlin | President and COO | 9,085 | $8.77K |
| Lawrence Lamb | EVP and CSO | 3,379 | $3.26K |
| Corinne Epperly | Director | 2,732 | $2.64K |
| Luba Greenwood | Director | 261 | $252 |
| Jeremy R. Graff | Director | 152 | $147 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INAB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.